NAFDAC Warns of Falsified Dostinex Tablets in Nigeria

The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted the public to the circulation of falsified Dostinex 0.5mg tablets in Nigeria. This warning follows confirmation from Pfizer Nigeria Ltd, the product's market authorization holder.

NAFDAC stated that these falsified, unlicensed, and unregistered versions of Dostinex have been identified, despite the legitimate registered product not yet being imported into Nigeria. The agency highlighted that these unregistered medications have not been evaluated, meaning their quality, safety, and efficacy cannot be guaranteed.

NAFDAC's zonal director has directed surveillance to remove unregistered products wherever found. Healthcare professionals and caregivers are advised to ensure that medications are sourced from authorized suppliers.

Patients are encouraged to report any adverse reactions to NAFDAC's offices or through their mobile application. The agency has reiterated the serious risks posed by falsified and tampered health products, especially following a recent safety alert regarding altered expiration dates linked to the illness of a four-month-old infant in Kaduna State.